Virksomhedsform
Aktieselskab
Etableret
1997
Størrelse
Mellemstore
Ansatte
128
Omsætning
593 MDKK
Bruttofortj.
193 MDKK
Primært resultat (EBIT)
20 MDKK
Årets resultat
56 MDKK
Egenkapital
290 MDKK
annonce

Flere nøgletal og analyser?

Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!

Rang Årets resultat

Rang i branche
15/444
"Top 10%"
Rang i Danmark
2.721/342.443
"Top 10%"

Direktion top 3

Bestyrelse top 3

Uffe Mark Hansen 1Bestyrelsesformand
Peter Drøidal 6Bestyrelsesmedlem
Johan Mikael Olof Kahlström 1Bestyrelsesmedlem

Legale ejere top 3

Tegningsregler

Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af en direktør i forening med et bestyrelsesmedlem

Stamoplysninger baseret på CVR

NavnNovartis Healthcare A/S
BinavneCiba-Geigy A/S, Sandoz A/S Vis mere
CVR20575786
AdresseEdvard Thomsens Vej 14, 3, 2300 København S
BrancheEngroshandel med medicinalvarer og sygeplejeartikler [464610]
Etableret17-12-1997 (26 år)
Første regnskabsperiode01-04-1997 til 31-12-1997
VirksomhedsformAktieselskab
Antal ansatte95 (årsværk:91)
ReklamebeskyttelseNej
RevisorKpmg P/S siden 06-01-2023
Regnskabsperiode01-01 til 31-12
Selskabskapital14.001.000 DKK
12.001.000 DKK (15-12-2006 - 18-08-2009)
10.001.000 DKK (14-12-2004 - 14-12-2006)
8.001.000 DKK (10-07-2002 - 13-12-2004)
8.000.000 DKK (17-12-1997 - 09-07-2002)
Vedtægter seneste15-05-2020

Formål

Selskabets formål er at drive handel, industri og finansiering samt anden dermed beslægtet virksomhed, herunder at drive virksomhed gennem datterselskaber

Regnskab

 202220212020
Valuta/enhed000' DKK000' DKK000' DKK
Omsætning
592.697
-16%
701.904
-30%
1.002.386
+4%
Bruttofortjeneste
193.399
+13%
170.533
-13%
196.791
+15%
Årets resultat
56.162
-34%
84.886
-34%
127.707
-
Egenkapital
289.921
+24%
233.759
+57%
148.873
+603%
Balance
942.616
0%
943.865
+15%
820.852
+10%

Ledelsesberetning

The income statement for 2022 shows a profit of DKK 56,162 thousand against a profit of DKK 84,886 last year, and the balance sheet at 31 December 2022 shows equity of DKK 289,921 thousand.
Actuals for the year 2022 didn’t reach the target set by the management. Sales being lower than target were partly driven by higher than anticipated LOE erosion (generic impact) as well as assumptions on winning certain tenders not materializing. There was also some impact from forward-buying in December 2021 which was not de-risked in the target.
In April 2022 Novartis globally announced a new organizational structure to accelerate growth and strengthen pipeline and increase productivity. This new simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity Integrating Pharmaceuticals and Oncology business units into an Innovative Medicines business with separate US and International commercial organizations will increase focus, strengthen competitiveness and drive synergies. This restructuring initiative has reduced the number of employees in Novartis Healthcare A/S. In terms of headcounts in payroll as of Dec 2022, there was no/low impact of TfG. Headcount has been reduced in 2023 and is reduced already at the time of issuing this annual report.
In August 2022 Novartis announced the intention to separate Sandoz business to create a standalone company by way of a 100% spin-off. For both the Innovative Medicines and Sandoz businesses, the spin-off would enable enhanced focus and the ability to pursue independent growth strategies. Sandoz is expected to deliver its next wave of growth based on the existing biosimilars pipeline of 15+ molecules, a strong and experienced management team and organization. Novartis aims to become a focused innovative medicines company with a stronger financial profile, and improved return on capital.
09-05-2023

Kort